East Region Formulary
NHS Scotland

Gynaecological cancer

The Oncology Online Quality System (OOQS) provides up-to-date quality-controlled Edinburgh Cancer Centre documentation, including Clinical Management Guidelines by tumour group, SACT lists and procedures. OOQS includes guidelines for managing conditions associated with malignancy and treatment related side-effects.

Gynaecology includes cancer of the ovary, endometrium, cervix, vagina and vulva. The SCAN Gynae Tumour Specific Group is a multi-disciplinary group made of health professionals from the South East of Scotland and meets 4 times a year.

A list of all formulary decisions relating to Gynaecological Cancer medicines can be viewed on the Formulary Decisions section of the website. Formulary decisions are agreed through SCAN and across all three Boards.

OOQS: Tumour Site (intranet) SCAN: Tumour Specific Groups - Gynaecological

Hormonal treatment of endometrial cancer
Medroxyprogesterone
Medroxyprogesterone 100mg tablets

300mg daily.

Medroxyprogesterone 200mg tablets

300mg daily.

Medroxyprogesterone 400mg tablets

300mg daily.

Megestrol
Megestrol 160mg tablets

160mg daily.

Prescribing Notes:

  • The position of specialist treatment in this condition pathway is not intended to guide on place in therapy. The place in therapy is directed by a consultant oncologist experienced in the management of advanced endometrial cancer, use is in line with relevant local or national guidance. Refer to gynaecological cancer formulary decisions and clinical management guidelines for more details.
  • Progestogens are occasionally used in frail patients with advanced endometrial cancer.
  • Progestogens should be used with caution in conditions that may worsen with fluid retention and in those susceptible to thromboembolism.

History Notes

01/03/2023

East Region Formulary content agreed.